132 related articles for article (PubMed ID: 30057641)
1. The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine.
Javan-Noughabi J; Rezapour A; Kassani A; Hatam N; Ahmadloo N
J Res Med Sci; 2018; 23():57. PubMed ID: 30057641
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran.
Hatam N; Askarian M; Javan-Noghabi J; Ahmadloo N; Mohammadianpanah M
Asian Pac J Cancer Prev; 2015; 16(18):8265-70. PubMed ID: 26745071
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
4. The use of paclitaxel in the management of early stage breast cancer.
Griffin S; Dunn G; Palmer S; Macfarlane K; Brent S; Dyker A; Erhorn S; Humphries C; White S; Horsley W; Ferrie L; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():15-22. PubMed ID: 19567209
[TBL] [Abstract][Full Text] [Related]
5. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.
Xu Q; Yuanyuan L; Jiejing Z; Jian L; Qingyu L; Lingya C; Ying L; Changchen S; Yangling L; Wei Y
Cost Eff Resour Alloc; 2021 Feb; 19(1):11. PubMed ID: 33622356
[TBL] [Abstract][Full Text] [Related]
7. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer.
Hong WS; Jeon JY; Kang SY; Jung YS; Kim JY; Ahn MS; Kang DK; Kim TH; Yim HE; An YS; Park RW; Kim KS
J Korean Surg Soc; 2013 Jul; 85(1):7-14. PubMed ID: 23833754
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.
Liubao P; Xiaomin W; Chongqing T; Karnon J; Gannong C; Jianhe L; Wei C; Xia L; Junhua C
Pharmacoeconomics; 2009; 27(10):873-86. PubMed ID: 19803541
[TBL] [Abstract][Full Text] [Related]
10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
[TBL] [Abstract][Full Text] [Related]
12. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
13. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett MJ; Li H; Burstein HJ; Punglia RS
Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
[TBL] [Abstract][Full Text] [Related]
15. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Burnell M; Levine MN; Chapman JA; Bramwell V; Gelmon K; Walley B; Vandenberg T; Chalchal H; Albain KS; Perez EA; Rugo H; Pritchard K; O'Brien P; Shepherd LE
J Clin Oncol; 2010 Jan; 28(1):77-82. PubMed ID: 19901117
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
Abraham J; Robidoux A; Tan AR; Limentani S; Sturtz K; Shalaby I; Alcorn H; Buyse ME; Wolmark N; Jacobs SA
Breast Cancer Res Treat; 2015 Jul; 152(2):399-405. PubMed ID: 26126970
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
[TBL] [Abstract][Full Text] [Related]
19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
20. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
Gadisa DA; Assefa M; Wang SH; Yimer G
J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
